Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575950 · ClinicalTrials.gov registry record · Phase 2
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT02575950 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 59 participants.
The verdict
NCT02575950, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.
Interventions
- DRUG Placebo
- DRUG LEO43204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575950
The ClinicalTrials.gov registry entry for NCT02575950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02575950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575950 about?
NCT02575950 is a clinical study titled "Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne". An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.
What is the current status of trial NCT02575950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2016-06. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02575950?
The interventions under investigation include: Placebo (DRUG), LEO43204 (DRUG).
Who is sponsoring clinical trial NCT02575950?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.